OOIR: Observatory of International Research

Papers

(The TQCC of Oncoimmunology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Loss of the extracellular protease ADAMTS1 reveals an antitumorigenic program involving the action of NIDOGEN-1 on macrophage polarization	99
Targeting 3D chromosomal architecture at the RANK loci to suppress myeloma-driven osteoclastogenesis	97
Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer	81
Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials	65
The endoplasmic reticulum chaperone BiP: a target for immunogenic cell death inducers?	65
Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition	64
Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors	62
Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors	59
Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status	59
Listeria-based vaccination against the pericyte antigen RGS5 elicits anti-vascular effects and colon cancer protection	57
T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction	55
Ferroptosis: friend or foe in cancer immunotherapy?	54
MicroRNA analysis of Natural Killer cell-derived exosomes: the microRNA let-7b-5p is enriched in exosomes and participates in their anti-tumor effects against pancreatic cancer cells	51
Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition	49
Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence	48
The anti-inflammatory cytokine IL-37 improves the NK cell-mediated anti-tumor response	46
LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma	42
Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response	42
PD-1 is expressed in cytotoxic granules of NK cells and rapidly mobilized to the cell membrane following recognition of tumor cells	41
Correction	39
CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival	39
CPT1C-positive cancer-associated fibroblast facilitates immunosuppression through promoting IL-6-induced M2-like phenotype of macrophage	39
Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8 ⁺ T cells eradicates peritoneal metastases in mouse models	38
Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer	37
IRE1α overexpression in malignant cells limits tumor progression by inducing an anti-cancer immune response	37

A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC	35
Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas	35
STING is significantly increased in high-grade glioma with high risk of recurrence	34
Targeting the activin receptor 1C on CD4+ T cells for cancer immunotherapy	33
Markers of tumor-associated macrophages and microglia exhibit high intratumoral heterogeneity in human glioblastoma tissue	33
PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis	33
Reprogramming monocyte-derived macrophages through caspase inhibition	33
Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates	33
Enhancement of tumor immunogenicity by the introduction of non- proteinogenic amino acid azetidine-2-carboxylic acid	33
Avelumab induces greater Fc-Fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to durvalumab	32
Improving STING agonist-based cancer therapy by inhibiting the autophagy-related protein VPS34	32
CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma model	31
Lactate/GPR81 recruits regulatory T cells by modulating CX3CL1 to promote immune resistance in a highly glycolytic gastric cancer	31
Immune sunrise: from the immunome to the cancer immune landscape	31
SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion	30
Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML	30
Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade	29
Interferon regulatory factor 4 plays a pivotal role in the development of aGVHD-associated colitis	29
A diversity outbred F1 mouse model identifies host-intrinsic genetic regulators of response to immune checkpoint inhibitors	29
Cell therapy for a rare disease- hairy cell leukemia variant	29
Tumor-infiltrating B cells produce tumor-specific antibodies and may contribute to suppressing tumor in head and neck squamous cell carcinoma	29
Immunogenic stress induced by local anesthetics injected into neoplastic lesions	29
Neoadjuvant immune checkpoint blockade triggers persistent and systemic T _reg activation which blunts therapeutic efficacy against metastatic spread of breast tumors	28
Liver metastases of colorectal cancer contain different subsets of tissue-resident memory CD8 T cells correlated with a distinct risk of relapse following surgery	28
The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology	28
Phenotypic characterization of spatial immune infiltration niches in non-small cell lung cancer	27
Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation	27
Chemokine switch regulated by TGF-β1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy	27
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases	26
Synergistic effect of combining sunitinib with a peptide-based vaccine in cancer treatment after microenvironment remodeling	26
Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer	26
Trial watch: beta-blockers in cancer therapy	26
Accumulation of tissue-resident natural killer cells, innate lymphoid cells, and CD8 ⁺ T cells towards the center of human lung tumors	26
Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors	26
A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination	26
Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy	25
TNFR2/CCR8 bispecific antibody enhances antitumor activity through depleting Ti-Tregs and boosting effector CD8 ⁺ T cell function	25
Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors	24
Spermidine rejuvenates T lymphocytes and restores anticancer immunosurveillance in aged mice	24
Candidate tumor-specific CD8 ⁺ T cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysis	24
Targeting coagulation to unlock antitumor immunity?	24
Surrogate markers of intestinal dysfunction associated with survival in advanced cancers	24
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response	23
Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)	23
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response	23
Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy	23
M2 macrophage-derived exosomes suppress tumor intrinsic immunogenicity to confer immunotherapy resistance	23
Interleukin-27 tackles immunosuppression in chronic lymphocytic leukemia	22
Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products	21
Mitochondrial DNA transfer between malignant cells and T lymphocytes shapes the cancer-immunity dialogue	21

MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4 ⁺ T cells in vivo	21
Schweinfurthin induces ICD without ER stress and caspase activation	21
Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancer	21
Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes	21
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression	21
Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade	20
Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinoma	20
Gasdermin E links tumor cell-intrinsic nucleic acid signaling to proinflammatory cell death for successful checkpoint inhibitor cancer immunotherapy	20
Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc)	20
Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)	20
CD8 ⁺ T cells in breast cancer tumors and draining lymph nodes: PD-1 levels, effector functions and prognostic relevance	20
CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies	20
A novel membrane-bound interleukin-2 promotes NK-92 cell persistence and anti-tumor activity	20
Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer	20
Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction	19
Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastoma	19
Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis	19
Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression	19
BCG-activation of leukocytes is sufficient for the generation of donor-independent innate anti-tumor NK and γδ T-cells that can be further expanded in vitro	19
Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer	19
Cell type-specific induction of ferroptosis to boost antitumor immunity	19
Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting	19
Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies	18
Low triglyceride levels are associated with increased risk of immune-related adverse events in patients receiving immune checkpoint inhibitors	18
Activation of endogenous glucocorticoids by HSD11B1 inhibits the antitumor immune response in renal cancer	18
Enriched circulating and tumor-resident TGF-β ⁺ regulatory B cells in patients with melanoma promote FOXP3 ⁺ Tregs	18
g-NK cells from umbilical cord blood are phenotypically and functionally different than g-NK cells from peripheral blood	18
High-grade serous ovarian cancer development and anti-PD-1 resistance is driven by IRE1α activity in neutrophils	18
Metabolic heterogeneity in tumor cells impacts immunology in lung squamous cell carcinoma	18
Small extracellular vesicles: multi-faceted tools for leukemia immune evasion in vivo	18
Piezo1 facilitates optimal T cell activation during tumor challenge	18
Non-pharmaceutical interventions to optimize cancer immunotherapy	17
Mycobacterial surface characters remodeled by growth conditions drive different tumor-infiltrating cells and systemic IFN-γ/IL-17 release in bladder cancer treatment	17
Regional immune mechanisms enhance efficacy of an autologous cellular cancer vaccine with intraperitoneal administration	17
Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome	17
Suppression of prostate cancer and amelioration of the immunosuppressive tumor microenvironment through selective immunoproteasome inhibition	17
Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy	17
The long-lasting expression of recombinant artLCMV following intraperitoneal administration exerts potent antitumor effects on tumor models of peritoneal carcinomatosis	17
Arsenic trioxide as an inducer of immunogenic cell death	17
LCVM infection generates tumor antigen-specific immunity and inhibits growth of nonviral tumors	17
QPCTL regulates macrophage and monocyte abundance and inflammatory signatures in the tumor microenvironment	16
CD4+ T cell-derived IL-22 enhances liver metastasis by promoting angiogenesis	16
Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden	16
CD4 ⁺ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts	16
How macrophages use extracellular calreticulin to chase their prey	15
Systemic administration of a viral nanoparticle neoadjuvant prevents lung metastasis development through emergency myelopoiesis	15
Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses	15
Are tumor-associated carbohydrates the missing link between the gut microbiome and response to immune checkpoint inhibitor treatment in cancer?	15
Cytoplasmic HMGB2 orchestrates CALR translocation in the course of immunogenic cell death	15
Tumor-associated macrophages promote intratumoral conversion of conventional CD4 ⁺ T cells into regulatory T cells via PD-1 signalling	15
Single-cell analysis of T lymphocytes infiltrating colorectal carcinoma: the dilemma of specificity	15
Extracellular vesicles released by cancer-associated fibroblast-induced myeloid-derived suppressor cells inhibit T-cell function	14
EphA2 and phosphoantigen-mediated selective killing of medulloblastoma by γδT cells preserves neuronal and stem cell integrity	14
Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer	14
The landscape of T-cell engagers for the treatment of follicular lymphoma	14
An SNP-dependent cancer-testis antigenic epitope serves as a promising immunotherapeutic target for cancer	14
Salmonella immunotherapy engineered with highly efficient tumor antigen coating establishes antigen-specific CD8+ T cell immunity and increases in antitumor efficacy with type I int	14
Human allogenic γδ T cells kill patient-derived glioblastoma cells expressing high levels of DNAM-1 ligands	14
Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases	14
Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor	14
Immunotherapy approaches for the treatment of diffuse midline gliomas	13
Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody	13
Metabolic regulation of the mitochondrial immune checkpoint	13
CD25 ^bright NK cells display superior function and metabolic activity under regulatory T cell-mediated suppression	13
Induction of cell death in malignant cells and regulatory T cells in the tumor microenvironment by targeting CD137	13
Near-infrared duocarmycin photorelease from a Treg-targeted antibody-drug conjugate improves efficacy of PD-1 blockade in syngeneic murine tumor models	13
Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors	13
Combined tumor-associated microbiome and immune gene expression profiling predict response to neoadjuvant chemo-radiotherapy in locally advanced rectal cancer	13
Expression of cartilage oligomeric matrix protein in periampullary adenocarcinoma is associated with pancreatobiliary-type morphology, higher levels of fibrosis and immune cell exclusion	13
Isolation of a tumor neoantigen specific CD8+ TCR from a skin biopsy of a vaccination site	13
Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival	13
Acquired DNA damage repairs deficiency-driven immune evolution and involved immune factors of local versus distant metastases in non-small cell lung cancer	13
Type I interferon induces cancer stem cells-mediated chemotherapy resistance	13
Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases	13
Cross-disease integration of single-cell RNA sequencing data from lung myeloid cells reveals TAM signature in in vitro model	13